I take it to mean they will do a deal for NASH by the end of...

I take it to mean they will do a deal for NASH by the end of calendar year 2018. I don't think they can fund the Phase III on their own so I presume a partner will be expected to cover that and Immuron will give up some upside as a result. Hopefully not too much based on the large market, no approved therapies and late stage of the product.

Though if you look at NEU, the deal they signed was viewed as disappointing even though they got $10m upfront (for US rights only) and the Phase III fully funded. I think we have a smaller following here but I think expectations of a deal are high due to competitors?

I like Whittpa's thinking

I can understand it being frustrating as there isn't a constant news flow but the company does deliver solid news when it does report.

The new director is a serious heavy hitter. I'm sure he would have connections all over the place plus would want his 2m options to be in the money.

I hope that they are working hard on a deal for NASH and that is the reason why it is quiet. I can't see any recent director buying which leads me to think they might not be able to buy due to trading windows (my take though conversely you could say they aren't buying because they aren't confident - GrandLodge own a fair bit though). I am happy to wait if it is a monster ($50m+ upfront haha).